| Autor: |
Pitter JG; Syreon Research Institute, 1142 Budapest, Hungary.; Division of Pharmacoeconomics, Faculty of Pharmacy, University of Pecs, 7624 Pecs, Hungary., Nagy L; Syreon Research Institute, 1142 Budapest, Hungary., Nagy B; Syreon Research Institute, 1142 Budapest, Hungary., Hren R; Syreon Research Institute, 1142 Budapest, Hungary.; Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia.; Institute of Mathematics, Physics, and Mechanics, 1000 Ljubljana, Slovenia. |
| Abstrakt: |
Primary demyelinating disorders of the central nervous system (CNS) include multiple sclerosis and the orphan conditions neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD). Curative technologies under development aim to selectively block autoimmune reactions against specific autoantigens while preserving the responsiveness of the immune system to other antigens. Our analysis focused on target patient selection for such developments, carefully considering the relevant clinical, regulatory, and market-related aspects. We found that the selection of patients with orphan conditions as target populations offers several advantages. Treatments for orphan conditions are associated with limited production capacity, qualify for regulatory incentives, and may require significantly shorter and lower-scale clinical programs. Furthermore, they may meet a higher acceptable cost-effectiveness threshold in order to compensate for the low numbers of patients to be treated. Finally, curative technologies targeting orphan indications could enter less competitive markets with lower risk of generic price erosion and would benefit from additional market protection measures available only for orphan products. These advantages position orphan conditions and subgroups as the most attractive target indications among primary demyelinating disorders of the CNS. The authors believe that after successful proof-of-principle demonstrations in orphan conditions, broader autoimmune patient populations may also benefit from the success of these pioneering developments. |
